BR112015021595A2 - anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno - Google Patents
anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígenoInfo
- Publication number
- BR112015021595A2 BR112015021595A2 BR112015021595A BR112015021595A BR112015021595A2 BR 112015021595 A2 BR112015021595 A2 BR 112015021595A2 BR 112015021595 A BR112015021595 A BR 112015021595A BR 112015021595 A BR112015021595 A BR 112015021595A BR 112015021595 A2 BR112015021595 A2 BR 112015021595A2
- Authority
- BR
- Brazil
- Prior art keywords
- binding fragments
- human
- antibodies
- antigen binding
- tgf
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 239000012634 fragment Substances 0.000 title abstract 5
- 239000013078 crystal Substances 0.000 abstract 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001134—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
resumo patente de invenção: "anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno". a presente invenção refere-se aos anticorpos ou os fragmentos de ligação ao antígeno dos mesmos que são concebidos para se ligarem ao fator de crescimento transformante ß (tgfß). os anticorpos seletivos das isoformas tgfß ou os fragmentos de ligação ao antígeno dos mesmos podem se ligar de maneira seletiva ao tgfß1 humano, em comparação com o tgfß2 humano e tgfß3 humano, ou podem se ligar de maneira seletiva a tgfß3 humano, em comparação com tgfß1 humano e tgfß2 humano. a concepção dos anticorpos ou os fragmentos de ligação ao antígeno dos mesmos é facilitada por meio de uma estrutura de co-cristal de um fragmento fab recombinante de gc1008 ligado a tgfß2 e por meio de uma outra estrutura de co-cristal da versão scfv do gc1008 ligado a tgfß1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361776430P | 2013-03-11 | 2013-03-11 | |
| PCT/US2014/023274 WO2014164709A2 (en) | 2013-03-11 | 2014-03-11 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015021595A2 true BR112015021595A2 (pt) | 2017-10-10 |
Family
ID=51659302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015021595A BR112015021595A2 (pt) | 2013-03-11 | 2014-03-11 | anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9783604B2 (pt) |
| EP (2) | EP2971048B1 (pt) |
| JP (1) | JP6495884B2 (pt) |
| KR (1) | KR102258457B1 (pt) |
| CN (1) | CN105229160B (pt) |
| AR (1) | AR095240A1 (pt) |
| AU (2) | AU2014249051B2 (pt) |
| BR (1) | BR112015021595A2 (pt) |
| CA (1) | CA2904847C (pt) |
| CY (1) | CY1121412T1 (pt) |
| DK (1) | DK2971048T3 (pt) |
| ES (2) | ES2713505T3 (pt) |
| HK (1) | HK1220731A1 (pt) |
| HR (1) | HRP20190201T1 (pt) |
| HU (1) | HUE042020T2 (pt) |
| IL (1) | IL241404B (pt) |
| LT (1) | LT2971048T (pt) |
| MX (1) | MX365385B (pt) |
| PL (1) | PL2971048T4 (pt) |
| PT (1) | PT2971048T (pt) |
| RU (1) | RU2681502C2 (pt) |
| SG (2) | SG11201507279XA (pt) |
| SI (1) | SI2971048T1 (pt) |
| TR (1) | TR201901415T4 (pt) |
| TW (2) | TWI613216B (pt) |
| UY (1) | UY35384A (pt) |
| WO (1) | WO2014164709A2 (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3036262A4 (en) | 2013-08-22 | 2017-03-01 | Acceleron Pharma Inc. | Tgf-beta receptor type ii variants and uses thereof |
| CA2971186A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| WO2016100232A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| US9884900B2 (en) | 2015-08-04 | 2018-02-06 | Acceleron Pharma Inc. | Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor |
| CN115925962A (zh) * | 2015-10-30 | 2023-04-07 | 豪夫迈·罗氏有限公司 | 铰链修饰的抗体片段和其制备方法 |
| PL3368571T3 (pl) * | 2015-10-30 | 2023-05-02 | The Regents Of The University Of California | Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania |
| KR20190007026A (ko) | 2016-05-17 | 2019-01-21 | 제넨테크, 인크. | 면역요법에서의 진단 및 사용을 위한 기질 유전자 특질 |
| GB201610044D0 (en) | 2016-06-08 | 2016-07-20 | Ucb Biopharma Sprl | Antibodies |
| AU2017310344A1 (en) * | 2016-08-11 | 2019-03-07 | Precithera, Inc. | TGF-β antagonist conjugates |
| US11701384B2 (en) | 2016-09-02 | 2023-07-18 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| PT3628049T (pt) | 2017-05-04 | 2023-07-03 | Acceleron Pharma Inc | Proteínas de fusão do recetor de tgf-beta tipo ii e utilizações dos mesmos |
| KR20200075860A (ko) | 2017-11-06 | 2020-06-26 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| JP7540994B2 (ja) * | 2018-07-11 | 2024-08-27 | スカラー ロック インコーポレイテッド | 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用 |
| TW202144408A (zh) * | 2020-03-19 | 2021-12-01 | 美商建南德克公司 | 同功型選擇性抗－ＴＧＦ－β抗體及其使用方法 |
| US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
| US20220162288A1 (en) | 2020-11-25 | 2022-05-26 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
| EP4281474A2 (en) * | 2021-01-21 | 2023-11-29 | Biolojic Design Ltd. | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof |
| CN112851819B (zh) * | 2021-01-25 | 2023-08-11 | 华中科技大学同济医学院附属同济医院 | 结合小鼠PD-L1和TGF-β的双特异性抗体及其制备方法与应用 |
| WO2022172085A2 (en) * | 2021-02-15 | 2022-08-18 | Takeda Pharmaceutical Company Limited | Cell therapy compositions and methods for modulating tgf-b signaling |
| CN113480645B (zh) * | 2021-07-16 | 2022-11-11 | 甘肃中科博瑞生物工程有限公司 | 一种抗幽门螺旋杆菌重组抗体、制备方法及用途 |
| WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
| WO2024077095A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| US6008011A (en) | 1991-10-31 | 1999-12-28 | Whitehead Institute For Biomedical Research | TGF-β type II receptor cDNAs |
| DE69232986T2 (de) | 1991-10-31 | 2003-12-11 | Whitehead Institute For Biomedical Research, Cambridge | TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG |
| RU2157406C2 (ru) * | 1993-08-10 | 2000-10-10 | Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх | НОВЫЙ ФАКТОР РОСТА/ДИФФЕРЕНЦИАЦИИ TGF-β-СЕМЕЙСТВА |
| IL110589A0 (en) | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
| GB9601081D0 (en) * | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| CA2301166A1 (en) | 1997-07-24 | 1999-02-04 | Yuan-Peng Zhang | Liposomal compositions for the delivery of nucleic acid catalysts |
| US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| EP2130532A1 (en) | 1999-01-05 | 2009-12-09 | University of Utah Research Foundation | Method for treating conditions associated with the accumulation of excess extracellular matrix |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| WO2001066140A1 (en) | 2000-03-09 | 2001-09-13 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| JP4564261B2 (ja) | 2002-01-22 | 2010-10-20 | ジェンザイム、コーポレーション | 慢性的移植片拒絶反応の治療と予防のためのＴＧＦ−β拮抗薬の使用 |
| JP2006525362A (ja) | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| BRPI0607639B1 (pt) | 2005-02-08 | 2022-04-05 | Genzyme Corporation | Moléculas de anticorpo humano ou fragmento de ligação a antígeno das mesmas que se ligam e neutralizam tgf-beta1, 2 e 3, uso das mesmas e composição farmacêutica |
| WO2007050793A2 (en) | 2005-10-25 | 2007-05-03 | The Johns Hopkins University | Methods and compositions for the treatment of marfan syndrome and associated disorders |
| AU2007227292B2 (en) | 2006-03-17 | 2012-04-12 | Biogen Ma Inc. | Stabilized polypeptide compositions |
| CA2649440A1 (en) | 2006-04-12 | 2007-10-25 | Genzyme Corporation | Methods of treating autoimmune diseases |
| HUE035575T2 (en) | 2006-10-03 | 2018-05-28 | Genzyme Corp | Use of TGF-beta antagonists to treat children at risk of developing bronchopulmonary dysplasia |
| ES2702049T3 (es) | 2009-04-24 | 2019-02-27 | Univ Vanderbilt | Inducción anti-TGF-beta de crecimiento óseo |
| SI2835053T1 (sl) | 2010-03-12 | 2016-09-30 | Genzyme Corporation | Kombinirana terapija za zdravljenje raka dojke |
| NZ624382A (en) * | 2010-09-01 | 2015-05-29 | Genzyme Corp | Treatment of myocardial infarction using tgf - beta antagonists |
-
2014
- 2014-03-11 RU RU2015143156A patent/RU2681502C2/ru active
- 2014-03-11 CA CA2904847A patent/CA2904847C/en active Active
- 2014-03-11 WO PCT/US2014/023274 patent/WO2014164709A2/en active Application Filing
- 2014-03-11 SG SG11201507279XA patent/SG11201507279XA/en unknown
- 2014-03-11 SI SI201431071T patent/SI2971048T1/sl unknown
- 2014-03-11 AU AU2014249051A patent/AU2014249051B2/en active Active
- 2014-03-11 UY UY0001035384A patent/UY35384A/es not_active Application Discontinuation
- 2014-03-11 PL PL14779440T patent/PL2971048T4/pl unknown
- 2014-03-11 HU HUE14779440A patent/HUE042020T2/hu unknown
- 2014-03-11 BR BR112015021595A patent/BR112015021595A2/pt not_active IP Right Cessation
- 2014-03-11 AR ARP140100849A patent/AR095240A1/es not_active Application Discontinuation
- 2014-03-11 MX MX2015012541A patent/MX365385B/es active IP Right Grant
- 2014-03-11 EP EP14779440.8A patent/EP2971048B1/en active Active
- 2014-03-11 PT PT14779440T patent/PT2971048T/pt unknown
- 2014-03-11 CN CN201480026283.5A patent/CN105229160B/zh active Active
- 2014-03-11 US US14/773,950 patent/US9783604B2/en active Active
- 2014-03-11 SG SG10201707021RA patent/SG10201707021RA/en unknown
- 2014-03-11 ES ES14779440T patent/ES2713505T3/es active Active
- 2014-03-11 TR TR2019/01415T patent/TR201901415T4/tr unknown
- 2014-03-11 TW TW103108359A patent/TWI613216B/zh active
- 2014-03-11 LT LTEP14779440.8T patent/LT2971048T/lt unknown
- 2014-03-11 EP EP18181808.9A patent/EP3415633B1/en active Active
- 2014-03-11 KR KR1020157027607A patent/KR102258457B1/ko active IP Right Grant
- 2014-03-11 ES ES18181808T patent/ES2845215T3/es active Active
- 2014-03-11 DK DK14779440.8T patent/DK2971048T3/en active
- 2014-03-11 TW TW106136054A patent/TWI664979B/zh active
- 2014-03-11 JP JP2016501191A patent/JP6495884B2/ja active Active
-
2015
- 2015-09-09 IL IL241404A patent/IL241404B/en active IP Right Grant
-
2016
- 2016-07-20 HK HK16108616.9A patent/HK1220731A1/zh unknown
-
2017
- 2017-08-07 US US15/670,631 patent/US10730936B2/en active Active
-
2018
- 2018-05-10 AU AU2018203261A patent/AU2018203261B2/en active Active
-
2019
- 2019-01-30 HR HRP20190201TT patent/HRP20190201T1/hr unknown
- 2019-01-31 CY CY20191100139T patent/CY1121412T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015021595A2 (pt) | anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno | |
| BR112017027778A2 (pt) | anticorpos para o fator xi e métodos de uso | |
| BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
| BR112017025693A2 (pt) | anticorpos anti-cd40 e seus usos | |
| BR112018006360A2 (pt) | anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso | |
| PH12016500943A1 (en) | Aplnr modulatros and uses thereof | |
| UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
| BR112017010094A2 (pt) | anticorpos compreendendo regiões constantes de cadeias pesadas modificadas | |
| UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
| BR112015027812A2 (pt) | processo contínuo de multietapa para purificação de anticorpos | |
| EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
| BR112016004413A2 (pt) | composições, preparação de anticorpo e método de purificação de um polipeptídeo recombinante e de tratamento de um distúrbio | |
| CO6620013A2 (es) | Anticuerpos hacia gdf8 humano | |
| BR112015022123A8 (pt) | Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit | |
| BR112013020500A8 (pt) | anticorpo isolado, recombinante ou purificado | |
| EA201690813A1 (ru) | Применение семафорин-4d-связывающих молекул для лечения нейродегенеративных нарушений | |
| EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| EA202091315A2 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
| EA201291065A1 (ru) | Антитела против vla-4 | |
| BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| BR112015012708A2 (pt) | anticorpos para bmp-6 | |
| BR112015021483A2 (pt) | arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer | |
| BR112017007877A2 (pt) | anticorpo ou fragmento do mesmo, epítopo em ccr6 humana solúvel, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição e imunoconjugado | |
| BR112014029219A8 (pt) | moléculas de ligação de il-6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2713 DE 03-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |